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Abstract  
We propose an end-to-end model to predict drug-drug interactions (DDIs) by employing graph-
augmented convolutional networks. And this is implemented by combining graph convolutional neural 
network with an attentive pooling network to extract structural relations between drug pairs and 
make DDI predictions. The experiment results suggest a desirable performance achieving ROC at 
0.988, F1-score at 0.956, and AUPR at 0.986. Besides, the model can tell how the two DDI drugs 
interact structurally by varying colored atoms. And this may be helpful for drug design during drug 
discovery.  
Introduction 
Drug-drug interactions (DDIs) account for over 30% of all adverse drug reactions (ADRs) cases and 
often occur when co-medicate more than two drugs. More alarmingly, it stays a significant ADR-
mediated morbidity every year[1], and this ramps up withdrawn-risks of a drug from the market and 
thus pulls a strong disincentive to drug development [2]. Though it is ideal for detecting all negative 
DDIs during clinical trials, DDIs-induced-ADRs cases are often reported at clinical uses and post-
marketing surveillance, which pose a severe threat to public health. A study concerning the relationship 
between DDIs and the mortality rate of elderly hospitalized patients concludes that over 62.77% of 
patients present at least one DDI, and this may amount strictly to the death of these patients[3]. Besides, 
DDIs also expand the length of stay and cost of hospitalization[4]. Thus, predicting potential DDIs at an 
early stage, to the most possibility, makes DDIs-induced-ADRs evitable concerning the public expenses 
and health security. To date, two primary strategies, including medical trials and computational 
approaches, have been introduced to predict DDIs. The former focuses on biological and clinical trials 
to identify whether drug pairs share the same biochemical reactions or pathways [5] and induce ADRs. 
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However, it is highly constrained to identify all possible DDIs by conducting studies on patients who are 
on co-mediations during the clinical trials, which are also time and money consuming. Accordingly, to 
reduce costs and make broad possible predictions of DDIs, the latter has gained a growing attention in 
recent years.  
By integrating biological and clinical trials and post-marketing surveillance (such as FDA Adverse 
Event Reporting System, FAERS), we can manually extract the feature vectors that represent DDIs drug 
pairs such as targets, phenotypes, side-effects, fingerprints, and so forth. Then using conventional 
supervised machine learning(ML) methods(like logistic regression(LR), random forest(RF), decision 
tree(DT), Naïve Bayes(NB),support vector machine(SVM)) to make predictions[6, 7].   
Recently, Deep learning (DL) methods have witnessed rapid development in predicting DDIs. One 
reason is that DL can automatically extract features of drug pairs efficiently and effectively than manual 
works under different DL structures. For example, graph convolutional networks(GCNs) have been 
successfully implemented in graph learning, and thereupon it is potent to learn drug structures that are 
analogous to graphs[8]. Another is a great amount of DDIs data we can collect from knowledge-based 
databases such as DrugBank[9], the Kyoto Encyclopedia of Genes and Genomes (KEGG)[10]. With a large 
amount of data, DL has successfully excessed conventional ML in DDI predictions[11, 12].     
In this paper, we propose a graph-augmented end-to-end neural network model that can predict 
DDIs (Figure 1). Specifically, we employ simplified molecular input line entry specification (SMILES) to 
extract graph topology (atoms stand for nodes, bonds for edges) for each drug separately that in each 
DDI pairs as inputs. Then a weight-shared graph convolutional neural network (GCNN) is applied to 
generate graph representations. After such GCNN layers, we embedded an attentive pooling network 
to calculate how two drugs interact. After a graph gather function, drug molecule representations in 
each pair are concatenated for DDIs representations, which are accepted by a deep neural network. 
Finally, a simple sigmoid function determines the final classification.   
Related works 
Various works related to predicting DDIs have been proposed, and they can be concluded as two 
types-knowledge embedding-based and similarity-based methods. The knowledge embedding-based 
model creates a DDI knowledge graph from knowledge databases, and implement embedding 
algorithms (e.g.RDF2Vec[13], PBG[14])[12] for fixed-vectors as network inputs, then applying deep 
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learning network to make predictions. While drug similarity-based methods employed to integrate 
similarities such as drug structural, target, side effects similarity, etc. by similarity algorithms. Besides, 
to extract the structural relations between drugs, recent works have applied molecular fingerprints as 
inputs [15] to feed Siamese networks, which gained an excellent prediction performance. Besides, the 
latter cares about the structural similarity between DDI pairs, and it is beneficial for the beginning of 
drug discovery.  
Learning a drug molecule also have two types. The one is to compute molecular SMILES to fixed-
length fingerprint(such as PubChem fingerprint 881bits[16], Extended-Connectivity Fingerprints 
(ECFPs)[17]) by algorithms, and the other is to denote SMILES to a graph, then apply GCNN to learn 
features and these trained features are suitable for different tasks.  
Attention mechanism has been widely used in vision, and natural language processing and several 
works have successfully brought this mechanism for biological mechanism explanation, especially to 
explain the relation between drug substructure and adverse reactions[18] and drug-target 
interactions[19]. And this currently has not been applied to explain the mechanism of DDIs. 
      
  
Figure 1 Overview of network architecture 
Figure 1 The inputs for the model are graph topology of drug pairs, for each drug in the dataset, the number 
of atoms is expanded to a max number 65. For each layer of GCNN, we adopt an attentive pooling network to make 
the alignment of two drugs and obtain attention vectors for each drug. After such layers, we respectively sum all 
attention vectors for each drug as one vector (hA,hB in the figure). Then concatenated hA,hB to feed fully-connected 
layers, and employ a sigmoid function to make final predictions. 
Material and methods 
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Problem statement 
The inputs of the network are graph topology 𝐺 = (𝑉, 𝐸)[8] in which 𝑉 is a set of atoms, and 𝐸 
is a set of bonds that connects two atoms. Given drug pair inputs, the model predicts 𝑦 ∈ {0,1}, where 
𝑦 = 1 suggests DDI existence of drug pairs. 
DDI extraction and graph construction 
Our DDIs dataset is collected from the DrugBank database [20] Version 5.1.1, which is a golden 
standard DDI dataset covering 294,980 DDIs(positive) cross 2,286 approved drugs. Besides, we 
randomly pair an equally-sized negative dataset from the approved drugs group and exclude the pairs 
in the positive. Note that randomly paired drugs do not mean there are no DDIs. Though this may 
influence the prediction performance, the results are still acceptable[21]. 
We use RDKit to transform drug SMILES string to graph topology, and the transformation procedure 
partially refers to the code https://github.com/HIPS/neural-fingerprint. According to Duvenaud et.al. 
[22], each drug SMILES is converted to a graph where the nodes representing atoms and edges 
representing bonds respectively, and the features for nodes and edges are one-hot vectors which 
denote the types ( 62 atom types for nodes,6 bond types for edges) where nodes and edges belong to. 
The input size for the network is the number of nodes in a minibatch and the length of nodes features 
(nodes, node features), which means the input tensor difference for each minibatch. Considering the 
shape inconformity issue of drug pairs for attentive pooling network, we zero-padded nodes numbers 
(65 nodes for each drug in our model determined by the max atom number of a drug in our dataset) to 
where the drug molecule with the largest number of atoms in our dataset. Accordingly, the input tensor 
for our model is (batch size, nodes, node features). To avoid the influences of these zero-padding nodes 
in an attentive pooling network, we also created masks to ensure zero probability after the SoftMax 
function in attentive pooling.   
Graph Convolutional Neural Network (GCNN)  
We apply GCNN to transform the graph topology of a drug structure to the continuous hidden drug 
representations. The intuition is to view a drug molecule as an undirect graph G, with atoms as nodes 
and bonds as edges. Then the algorithm computes a molecule graph to a fixed size vector 𝑟𝑔  by 
aggregating the hidden representation 𝑟𝑣
𝑅  of each atom in a molecule graph.  
 The 𝑟𝑣
𝑅  for each atom in a molecule graph is calculated as follows:  
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                     𝑓𝑣
𝐿+1 = 𝑟𝑣
𝐿 + 𝛴𝑢𝜖𝑁(𝑣)𝑟𝑢
𝐿  (1) 
                     𝑟𝑣
𝐿+1 =  𝜎(𝑓𝑣
𝐿+1𝐻𝐿
𝑁(𝑣)
)  (2) 
Where L = 1 to R, R denotes numbers of layers(radii) for GCNN. 𝑟𝑣
𝐿  is the hidden representation in 
the radius L. 𝑁(𝑣) is the neighbors of 𝑣. And 𝐻𝐿
𝑁(𝑣)
 is a weight matrix. 𝜎 in our model equals a relu 
function. Before propagation, 𝑟𝑣
𝑅  is initialized by the atom features of 𝑣. 
 Then GCNN aggregates the hidden representation 𝑟𝑣
𝑅  of each atom to final graph 
representations.    
                     𝑟𝑔 = ∑ 𝑠𝑜𝑓𝑡𝑚𝑎𝑥(𝑟𝑣
𝐿𝑊𝐿)𝑣,𝐿  (3) 
Note that the equation (3) are omitted for attention implement and interpretability purpose. When 
initializing 𝑟𝑣
𝑅, the atom features and the bond features are set as a 62 and 6-dimensional one-hot 
vector, respectively. Besides, in our network, we set radius R which determines the times the network 
will iterate as four. 
Siamese network  
Siamese network has been successfully adopted in image and text matching and visual tracking[23-
25], Shortly speaking, the Siamese network is to evaluate the similarity of the two input samples by two 
weight shared sub-networks. Mapping DDI prediction, we take the view that drug pairs with DDIs may 
have a high-level structural relation. Accordingly, we add two weight-shared GCNN as sub-networks of 
Siamese, trying to learn molecule sub-structures that contribute to DDIs. 
Attentive pooling network 
The attention mechanism is one of the research hotspots in vision and natural language 
processing (NPL) field. Network with attention calculates the matching degree between input 
sequences and output vectors, and a high matching degree gains a high attention weight, which 
can selectively focus on the important spot of inputs, thus augment the performance of models. 
To figure out how drugs interact, we extend our model with an attentive pooling network[26], 
which is a two-way attention mechanism that builds a close connection between the two inputs 
pairs (question Q and answer A in Santos Cd et.al.). The algorithms apply over the outputs of CNN 
or LSTM to compute a soft alignment G = 𝑡𝑎𝑛ℎ(𝑄𝑇𝑊𝐴) , which conveys the interaction 
correlations scores between Q and A. Finally, applying a column-wise and row-wise max-pooling 
over G followed by a normalized operation SoftMax, the two-sides separately integrate mutual 
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information.  
For our model, given P = 𝑡𝑎𝑛ℎ(𝐴𝑇𝑊𝐵),where𝐴,B represent 𝐴 = 𝑀𝐻𝑎×𝐿𝑎 and 𝐵 = 𝑀𝐻𝑏×𝐿𝑏 
Respectively. Where 𝐻𝑎 and 𝐻𝑏 are the hidden space dimensions of each drug in pairs, while 𝐿𝑎 
and 𝐿𝑏 are the number of atoms of each drug in pairs. 𝑊 = 𝑀
𝐻𝑎×𝐻𝑏 is a trainable weight matrix. 
Model training 
We split our dataset into train and test dataset with radio 9:1. And perform the hyperparameter 
optimization through a 5-fold cross-validation test. We employed minibatch for training with Adam 
optimizer with learning rate 0.001; we hold the number of GCNN layers as four with the same units 50. 
As for the attentive pooling network, the Xavier initializer [27] is used to initialize weights. Besides, three 
fully connected layers are applied with the same units 100. The model are trained for 100 epochs with 
each epoch 200 steps. Except for the activation sigmoid for the final classification, all the activation 
functions are relu. 
In training, the DDI classification model is conducted by minimizing cross-entropy loss function 
𝐿𝑖 = − ∑ 𝑦𝑖log (?̂?𝑖
𝑛
𝑖=1 ) where 𝑖 = 1, … , 𝑛 given a dataset 𝐷 = {𝐷1𝑖 , 𝐷2𝑖 , 𝑦𝑖}, 𝐷1, 𝐷2 are input drug 
pairs. 
Results  
Analysis of DDI prediction 
 
 
 
 
 
 
Table 1 Comparison crosses the state-of-the-art DDI prediction models. 
Table 1 shows the model performance of GCNN with Attention and the comparison with advanced 
DDI prediction models. From the table, we can notice that our model outperforms most of the models 
except for Guy Shtar et al. s’ work when concerning ROC. Besides, the F1-score and AUPR score achieved 
0.956 and 0.986, respectively, that overpass all the listed models.   
Case study for interpretability 
Model ROC F1-score AUPR 
IDNDDI[28] 0.969 — — 
Karim M.R et al.[12] — 0.92 0.940 
R. Celebi et al.[21] 0.932 0.860 — 
Guy Shtar et al[29] 0.991 — 0.960 
GCNN + Attentive pooling 0.988 0.956 0.986 
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A key advantage of our model over baselines is the interpretability, where we can highlight the 
drug substructures that contribute to DDIs, and this, to some extent, helps explain the mechanism of 
DDIs incidences. During drug design, it is also helpful for experts to focus on the undesirable 
substructures of candidate chemicals. With the attention mechanism, we consider that the highest 
attention weights of nodes with their neighbors in drug pairs have the closest relation to DDI. Note that, 
the outputs of different layers for attentive pooling in GCNN contribute to different attention weights. 
To visualize, we compare attention weights cross each layer, and the attention weights with the highest 
one will be chosen for visualization.   
Celecoxib (a kind of a nonsteroidal anti-inflammatory drug) and Mephenytoin (designed for 
treating refractory partial epilepsy) have been observed CYP2D6-associated drug-drug interactions, and 
this may lead to potential adverse effects. The hydroxylation of celecoxib inhibits the Cytochrome P450 
2D6 (CYP2D6) (an enzyme that in humans is encoded by the CYP2D6 gene)[30], which result in the O-
demethylation of dextromethorphan in human liver. To conduct this case study, we downloaded the 
two drug SMILES from DrugBank (Accession Number DB00482 and DB00532 respectively). Firstly, we 
predicted the interaction between the two drugs as positive with confidence 0.97, and by comparing 
the attention weights cross GCNN layers, attention weights from layer one is chosen for a highlight. We 
then used rdkit to visualize the highlighted atoms from the two drugs (Figure 2), and their weights color 
all atoms from high to low. We found that the highlighted atoms are correctly showed the sites where 
the two drugs interact according to the literature[30].  
         
 
Figure 2 The highlighted atoms of the interaction drugs (Celecoxib and Mephenytoin).  
Conclusions 
We have presented an end-to-end model to predict DDIs and the experimental results show that 
this model can achieve desirable prediction performance. And with the attention mechanism 
embedded in our model, the interaction mechanism of drugs can be interpreted by highlight atoms. 
Celecoxib Mephenytoin 
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And this may help for drug discovery and predict the potential DDI pairs.  
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